Found: 5
Select item for more details and to access through your institution.
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 9, p. 845, doi. 10.1002/ajh.24782
- By:
- Publication type:
- Article
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 1, p. 7, doi. 10.1002/ajh.24568
- By:
- Publication type:
- Article
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2837, doi. 10.1007/s00277-024-05735-7
- By:
- Publication type:
- Article